Comments on the FDA’s Proposed Rule: Bill Morice, M.D., Ph.D.

Answers from the Lab

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the U.S. Food and Drug Administration’s (FDA) proposed rule on laboratory-developed tests (LDTs) and the comments Mayo Clinic submitted to the FDA.

Their discussion includes:

  • How Mayo Clinic responded in its comments to the FDA on the proposed rule on LDTs.
  • What comes next after the public comment period has closed effective Dec. 4.
  • Quality management systems that are currently in place for laboratories.
  • How changes in regulation could impact laboratory operations, patient care, access to testing, and innovation.

Podcast episode

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Podcast episode in video format

Answers from the Lab is a Mayo Clinic Laboratories curated podcast sharing knowledge and advancements regarding the state of testing, laboratory science, and the people who make it all happen behind the scenes. 

Click here

Information in this post was accurate at the time of its posting.

Luci Gens

Luci Gens is a marketing manager at Mayo Clinic Laboratories. She joined Mayo Clinic in 2022 and has over ten years of experience in hospital-based marketing and communications.

Related Posts
Being a Lifelong Learner
The Rapid Evolution of Artificial Intelligence: Bill Morice, M.D., Ph.D.
Global Surgery Hackathon: Lessons in Healthcare Systems